HK1243444A1 - 長效的ctp修飾的生長激素多肽的製備方法 - Google Patents

長效的ctp修飾的生長激素多肽的製備方法

Info

Publication number
HK1243444A1
HK1243444A1 HK18103050.1A HK18103050A HK1243444A1 HK 1243444 A1 HK1243444 A1 HK 1243444A1 HK 18103050 A HK18103050 A HK 18103050A HK 1243444 A1 HK1243444 A1 HK 1243444A1
Authority
HK
Hong Kong
Prior art keywords
methods
growth hormone
long acting
producing long
modified growth
Prior art date
Application number
HK18103050.1A
Other languages
English (en)
Inventor
奧倫．赫什科維茨
勞拉．莫斯科維奇
Original Assignee
Opko生物科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko生物科學有限公司 filed Critical Opko生物科學有限公司
Publication of HK1243444A1 publication Critical patent/HK1243444A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0633—Workflow analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
    • G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0201—Market modelling; Market analysis; Collecting market data
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Human Resources & Organizations (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Strategic Management (AREA)
  • Biotechnology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Economics (AREA)
  • Development Economics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Educational Administration (AREA)
  • General Business, Economics & Management (AREA)
  • Game Theory and Decision Science (AREA)
  • Marketing (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Finance (AREA)
  • Accounting & Taxation (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)
HK18103050.1A 2014-12-10 2018-03-02 長效的ctp修飾的生長激素多肽的製備方法 HK1243444A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462090104P 2014-12-10 2014-12-10
US201462090124P 2014-12-10 2014-12-10
US201462090116P 2014-12-10 2014-12-10
PCT/IL2015/051196 WO2016092549A1 (en) 2014-12-10 2015-12-10 Methods of producing long acting ctp-modified growth hormone polypeptides

Publications (1)

Publication Number Publication Date
HK1243444A1 true HK1243444A1 (zh) 2018-07-13

Family

ID=56106835

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103050.1A HK1243444A1 (zh) 2014-12-10 2018-03-02 長效的ctp修飾的生長激素多肽的製備方法
HK18105854.4A HK1246322A1 (zh) 2014-12-10 2018-05-07 長效的ctp修飾的多肽製備方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18105854.4A HK1246322A1 (zh) 2014-12-10 2018-05-07 長效的ctp修飾的多肽製備方法

Country Status (22)

Country Link
US (3) US20180111974A1 (zh)
EP (4) EP4253407A3 (zh)
KR (3) KR20200118505A (zh)
CN (1) CN107438623B (zh)
AU (2) AU2015358890B2 (zh)
CO (1) CO2017006870A2 (zh)
EA (1) EA201791275A1 (zh)
ES (1) ES2943359T3 (zh)
HK (2) HK1243444A1 (zh)
HR (1) HRP20230405T8 (zh)
IL (2) IL252778B (zh)
MX (2) MX2017007634A (zh)
NZ (1) NZ733113A (zh)
PE (1) PE20171380A1 (zh)
PH (1) PH12017501089A1 (zh)
PL (1) PL3230309T3 (zh)
RU (2) RU2021103436A (zh)
SG (1) SG11201704706RA (zh)
SI (1) SI3230309T1 (zh)
TW (2) TWI746427B (zh)
WO (2) WO2016092549A1 (zh)
ZA (1) ZA201704595B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
TWI746427B (zh) 2014-12-10 2021-11-21 以色列商歐科生物製品有限公司 製造長效ｃｔｐ修飾的多肽之方法
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
AU2017296352A1 (en) * 2016-07-11 2019-02-21 Opko Biologics Ltd. Long-acting coagulation factor VII and methods of producing same
RU2652884C1 (ru) * 2016-11-25 2018-05-03 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2021005604A1 (en) * 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
WO2022197961A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Methods of administering long-acting growth hormone polypeptides
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE68917883T2 (de) 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
EP0394788B1 (en) * 1989-04-28 1994-08-03 Miles Inc. Large scale fermenter inoculation with frozen cells
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1994024148A1 (en) * 1993-04-20 1994-10-27 Washington University Modified protein and peptide pharmaceuticals
ES2139081T3 (es) * 1994-06-17 2000-02-01 Applied Res Systems Ars Holding N V Composiciones farmaceuticas que contienen la hormona humana del crecimiento.
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
CN1847265A (zh) * 2005-04-15 2006-10-18 上海市计划生育科学研究所 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途
US20140113860A1 (en) * 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US9249407B2 (en) * 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
WO2012051147A1 (en) * 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
MY172539A (en) 2012-02-14 2019-11-30 Opko Biologics Ltd Long-acting coagulation factors and methods of producing same
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
MY167814A (en) 2012-04-19 2018-09-26 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
BR122020018510B1 (pt) * 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
JP6464145B2 (ja) * 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
TWI746427B (zh) 2014-12-10 2021-11-21 以色列商歐科生物製品有限公司 製造長效ｃｔｐ修飾的多肽之方法
ES2893616T3 (es) * 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos

Also Published As

Publication number Publication date
ES2943359T3 (es) 2023-06-12
HK1246322A1 (zh) 2018-09-07
MX2017007634A (es) 2017-08-28
EA201791275A1 (ru) 2017-12-29
IL252778B (en) 2021-09-30
CO2017006870A2 (es) 2018-01-05
EP4253407A2 (en) 2023-10-04
AU2019203609A1 (en) 2019-06-13
EP4212546A1 (en) 2023-07-19
AU2015358890A1 (en) 2017-07-20
MX2017007635A (es) 2017-09-11
ZA201704595B (en) 2019-06-26
CN107438623A (zh) 2017-12-05
EP3240564A4 (en) 2018-05-30
TW202231657A (zh) 2022-08-16
AU2019203609B2 (en) 2021-02-25
EP3230309A1 (en) 2017-10-18
CN107438623B (zh) 2023-07-14
RU2017123789A3 (zh) 2019-01-10
RU2743295C2 (ru) 2021-02-16
HRP20230405T1 (hr) 2023-09-01
PE20171380A1 (es) 2017-09-15
AU2015358890B2 (en) 2019-06-13
US20160168588A1 (en) 2016-06-16
EP3230309B1 (en) 2023-03-29
IL252788B (en) 2021-09-30
WO2016092549A1 (en) 2016-06-16
SI3230309T1 (sl) 2023-08-31
WO2016092550A3 (en) 2016-08-04
KR20170086664A (ko) 2017-07-26
EP4253407A3 (en) 2023-12-06
HRP20230405T8 (hr) 2023-09-29
TWI746427B (zh) 2021-11-21
KR20220058564A (ko) 2022-05-09
PH12017501089A1 (en) 2017-10-18
KR102164352B1 (ko) 2020-10-13
RU2017123789A (ru) 2019-01-10
US20210371487A1 (en) 2021-12-02
PL3230309T3 (pl) 2023-08-28
EP3240564A2 (en) 2017-11-08
WO2016092550A2 (en) 2016-06-16
KR20200118505A (ko) 2020-10-15
BR112017012498A2 (pt) 2018-07-31
IL252788A0 (en) 2017-08-31
TW201638105A (zh) 2016-11-01
RU2021103436A (ru) 2021-02-25
SG11201704706RA (en) 2017-07-28
US20180111974A1 (en) 2018-04-26
KR102527180B1 (ko) 2023-04-27
IL252778A0 (en) 2017-08-31
NZ733113A (en) 2020-09-25

Similar Documents

Publication Publication Date Title
HK1243444A1 (zh) 長效的ctp修飾的生長激素多肽的製備方法
SG11201608454XA (en) Methods of controlling nanowire morphology
EP3116851A4 (en) Analogs of fexaramine and methods of making and using
SI3368571T1 (sl) Polipeptidi odzivni na transformirajoči rastni faktor-beta in postopki njihove uporabe
HK1223283A1 (zh) 製備注射液的方法
GB2522719B (en) Method of manufacture
HUP1400114A2 (en) Method for the production of peptides
SG11201608761PA (en) Methods of cellular reprogramming
HK1244227A1 (zh) 長效生長激素劑型
SG11201609173YA (en) Method of producing nylon
IL258981A (en) Methods for the production of proteins
EP3180296A4 (en) Methods of producing alkylfurans
IL252712A0 (en) Method for protein production
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
GB2522716B (en) Method of manufacture
IL249130B (en) Preparation of piperidine-4-carbothioamide
GB201402229D0 (en) Method of making an airdam
HK1232253A1 (zh) 生產多肽的方法
GB201413590D0 (en) Method of depositing diamond
AU354382S (en) Lounge setting
AU354314S (en) Lounge setting
GB201418283D0 (en) Production of anti-microbial peptides